NSC117079|500363-63-3|-陌孚医药/Medlife

您当前的位置：

NSC117079

目录号: PL09592 纯度: ≥98%

CAS No. :500363-63-3

商品编号	规格	价格	会员价
PL09592-5mg	5mg	¥3053.00	请登录
PL09592-10mg	10mg	¥5304.00	请登录
PL09592-25mg	25mg	¥10608.00	请登录
PL09592-50mg	50mg	¥18483.00	请登录
PL09592-100mg	100mg	¥31341.00	请登录
PL09592-200mg	200mg	询价	询价
PL09592-500mg	500mg	询价	询价
PL09592-10mM*1mLinDMSO	10mM*1mLinDMSO	¥3359.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	NSC117079
中文别名	化合物 T12260
英文名称	NSC117079
英文别名	NSC117079;Probes1_000352;Probes2_000019;NCIStruc1_001556;NCIStruc2_001807;BDBM50328821;NCGC00014173;NCI117079;NCI60_000393;A16894;1-Amino-9,10-dioxo-4-(3-sulfamoylanilino)anthracene-2-sulfonic acid;2-Anthracenesulfonic acid, 1-amino-4-[[3-(aminosulfonyl)phenyl]amino]-9,10-dihydro-9,10-dioxo-
Cas No.	500363-63-3
分子式	C₂₀H₁₅N₃O₇S₂
分子量	473.48
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	NSC117079是新型的 PHLPP 抑制剂。
生物活性	NSC117079 is a novel PHLPP inhibitor.
性状	Solid
IC50 & Target[1][2]	PHLPP
体外研究(In Vitro)	NSC-117079 at 30 μM induces neutrophil adhesion to plated fibrinogen from 9.0±2.4% to 27.0±8.0% and enhanced neutrophil adhesion caused by 50 ng/mL GM-CSF from 22.9±6.0% to 47.6±10.9%. Neutrophil adhesion is followed by neutrophil transendothelial migration. Results suggest that PHLPP inhibitor NSC-117079 is effective in preventing Akt from dephosphorylation in neutrophils, and Akt phosphatase PHLPP serves to attenuate neutrophil adhesion but not migration. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	A single intraarticular injection of the Phlpp inhibitor NSC117079 attenuates mechanical allodynia and slows articular cartilage degradation in joints with a destabilized meniscus. Animals treated with the Phlpp inhibitor seven weeks after injury maintain normal activity levels, while those in the control group travel shorter distances and are less active three months after the joint injury. NSC117079 also increases production of cartilage extracellular matrix components (glycosaminoglycans and aggrecan) in over 90% of human articular cartilage explants from osteoarthritis patients and increased phosphorylation of Phlpp1 substrates (AKT2, ERK1/2 and PKC) in human articular chondrocytes. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Jackson TC, et al. Pharmacological inhibition of pleckstrin homology domain leucine-rich repeat protein phosphatase is neuroprotective: differential effects on astrocytes. J Pharmacol Exp Ther. 2013 Nov;347(2):516-28. [2]. Zhu X, et al. Regulation Of Neutrophil Adhesion And Migration By Ph Domain And Leucine Rich Repeat Protein Phosphatase. A35 RECENT ADVANCES IN PHAGOCYTE BIOLOGY / Thematic Poster Session / Sunday, May 20/8:15 AM-4:30 PM / Area G (Hall D, North Building, Lower Level), Moscone Center

溶解度数据	In Vitro: DMSO : 50 mg/mL (105.60 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation